肺癌亚临床间质性肺病 thoracic 放疗后放射性肺炎危险因素
多因素分析显示平均肺剂量≥12 Gy是≥2级RP的显著危险因素,既往吉西他滨化疗、V5≥50%及亚临床ILD累及≥25%肺体积与≥3级RP显著相关。
要点
- 亚临床ILD肺癌患者胸部IMRT后1年≥2级RP累积发生率为51.0%。
- 平均肺剂量≥12 Gy是≥2级RP的显著危险因素(p=0.049)。
- 既往吉西他滨化疗、V5≥50%、ILD累及≥25%肺体积增加≥3级RP风险。
核心结论
- 平均肺剂量是≥2级RP的显著危险因素。
- 既往吉西他滨化疗、V5≥50%及亚临床ILD累及≥25%肺体积的患者≥3级RP风险增加。
研究设计与样本
- 回顾性分析2016年1月至2017年12月在本机构接受胸部调强放疗(处方剂量≥50 Gy)的肺癌合并亚临床ILD患者。
主要发现
- 1年≥2级和≥3级RP累积发生率分别为51.0%和20.9%。
- 多因素分析中平均肺剂量≥12 Gy与≥2级RP显著相关(p=0.049)。
- 既往吉西他滨化疗(p=0.046)、V5≥50%(p=0.040)、亚临床ILD累及≥25%肺体积(p=0.024)与≥3级RP显著相关。
关键数值与推荐
- 平均肺剂量≥12 Gy为≥2级RP的显著危险因素(p=0.049)。
- 既往吉西他滨化疗(p=0.046)、V5≥50%(p=0.040)、亚临床ILD累及≥25%肺体积(p=0.024)与≥3级RP显著相关。
临床怎么用
- 对肺癌合并亚临床ILD患者行胸部IMRT时,应关注平均肺剂量、V5及ILD累及肺体积。
- 既往接受吉西他滨化疗者需警惕≥3级RP风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have found that patients with subclinical interstitial lung disease (ILD) are highly susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. In the present study we aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy in lung cancer patients with subclinical ILD. METHODS: We retrospectively analyzed data from lung cancer patients with subclinical ILD who were treated with thoracic intensity-modulated radiation therapy with a prescribed dose of ≥ 50 Gy in our institution between January 2016 and December 2017. RESULTS: Eighty-seven consecutive lung cancer patients with subclinical ILD were selected for the study. The median follow-up period was 14.0 months. The cumulative incidence of grades ≥ 2 and ≥ 3 RP at one year was 51.0% and 20.9%, respectively. In the multivariate analysis, a mean lung dose ≥ 12 Gy was a significant risk factor for grade ≥ 2 RP (p = 0.049). Chemotherapy with gemcitabine in the past, V5 ≥ 50%, and subclinical ILD involving ≥ 25% of the lung volume were significantly associated with grade ≥ 3 RP (p = 0.046, p = 0.040, and p = 0.024, respectively). CONCLUSION: Mean lung dose is a significant risk factor for grade ≥ 2 RP. Lung cancer patients who have received chemotherapy with gemcitabine in the past, V5 ≥ 50%, and those with subclinical ILD involving ≥ 25% of lung volume have an increased risk of grade ≥ 3 RP in lung cancer patients with subclinical ILD.
引用
- Li F, Liu H, Wu H, et al. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy. Radiat Oncol. 2021. PMID: 33849579. doi:10.1186/s13014-021-01798-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。